Argun Akçakanat

Inhibitors of IAP/XIAP enhance activity of sacituzumab govitecan

Abstract TROP2 antibody-drug conjugate sacituzumab govitecan (SG) is approved for treatment of advanced breast cancer. However, intrinsic and acquired resistance occur, leading to a need for novel therapies. We hypothesized that antagonists of inhibitor of apoptosis protein (IAP)...